RT Journal Article
SR Electronic
T1 Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20134031
DO 10.1101/2020.06.17.20134031
A1 Francesco Salton
A1 Paola Confalonieri
A1 Pierachille Santus
A1 Sergio Harari
A1 Raffaele Scala
A1 Simone Lanini
A1 Valentina Vertui
A1 Tiberio Oggionni
A1 Antonella Caminati
A1 Vincenzo Patruno
A1 Mario Tamburrini
A1 Alessandro Scartabellati
A1 Mara Parati
A1 Massimiliano Villani
A1 Dejan Radovanovic
A1 Sara Tomassetti
A1 Claudia Ravaglia
A1 Venerino Poletti
A1 Andrea Vianello
A1 Anna Talia Gaccione
A1 Luca Guidelli
A1 Rita Raccanelli
A1 Paolo Lucernoni
A1 Donato Lacedonia
A1 Maria Pia Foschino Barbaro
A1 Stefano Centanni
A1 Michele Mondoni
A1 Matteo Davì
A1 Alberto Fantin
A1 Xueyuan Cao
A1 Lucio Torelli
A1 Antonella Zucchetto
A1 Marcella Montico
A1 Annalisa Casarin
A1 Micaela Romagnoli
A1 Stefano Gasparini
A1 Martina Bonifazi
A1 Pierlanfranco D’Agaro
A1 Alessandro Marcello
A1 Danilo Licastro
A1 Barbara Ruaro
A1 Maria Concetta Volpe
A1 Reba Umberger
A1 Umberto Meduri
A1 Marco Confalonieri
YR 2020
UL http://medrxiv.org/content/early/2020/06/25/2020.06.17.20134031.abstract
AB Background In hospitalized patients with COVID-19 pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.Methods We conducted a multicenter, observational study to explore the association between exposure to prolonged, low-dose, MP treatment and need for ICU referral, intubation or death within 28 days (composite primary endpoint) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.Results Findings are reported as MP (n=83) vs. control (n=90). The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 ± 9.0 vs. 17.5 ± 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the two groups (p=0.84).Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Randomized controlled studies are needed to confirm these findings.Registration ClinicalTrials.gov. Identifier: NCT04323592Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04323592Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04323592?term=confalonieri&draw=2&rank=1 Funding StatementThis material is the result of work supported with the resources and use of facilities at the University Hospital of Trieste and Memphis VA Medical Center. The contents of this commentary do not represent the views of the US Department of Veterans Affairs nor of the United States or Italian Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the referral Ethics Committee for the Coordinating Centre (University Hospital of Trieste, #CEUR-2020-Os-052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on reasonable external request.